Roadmap

Through the development of a product-specific roadmap we highlight strategic requirements and define tactical implementation activities. Our roadmaps outline the challenges that need to be addressed at global and country-specific levels. Our roadmaps define the detailed activities that will be required to meet the demands of payers and other key stakeholders, including patients and clinicians. We use our existing local and global knowledge, supplemented with new research, to comprehensively understand the evidence generation activities that will be required to meet the needs of each market of interest. We map these out across the drug development timeline to ensure that robust and relevant evidence is available for communication in a timely manner.

What does a roadmap look like?

Our roadmaps identify:

• Key market access challenges and requirements
• Evidence required, particularly for reimbursement and health technology assessment (HTA)
• Gaps in existing evidence generation plans
• Strategies and tactical plans to address the data gaps
• Specific evidence needs mapped out at country level
• Global and country-specific action plans
• Potential landscape, HTA policy, and competitor developments
• Critical success factors and priorities for evidence generation
• Timing of value communication and dossier development
• Strategic and tactical HEOR/market access recommendations

Our roadmaps are critical for informing trial design, including choice of comparators, target populations, sub-groups, and relevant outcomes, and are most effective when devised during early drug development. Our extensive experience in HTA and value proposition development ensures that our roadmaps address the needs of all key decision-makers across the lifecycle of the brand.